Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA)

NCT06409481 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Xinxiang Medical College as lead sponsor.

NCT NCT06409481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06409481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA)
Lead sponsor
The First Affiliated Hospital of Xinxiang Medical College
Phase
Observational
Overall status
Unknown status
Start date
June 1, 2024
Completion date
October 30, 2024
Enrollment
800,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, cardiac diseases, cardiovascular diseases, vascular diseases